Hikma Pharmaceuticals PLC 2023 SR
The report highlights Hikma's commitment to advancing health and wellbeing, empowering people, protecting the environment, and building trust. Key achievements in 2023 include a 15% reduction in Scope 1 and 2 emissions since 2020, donating $4.9 million worth of medicines, and achieving a 98% completion rate for ethics and compliance training. The company also focused on diversity, aiming for at least 35% women in leadership by 2025, and conducted energy audits across several MENA sites. Furthermore, Hikma aligned its reporting with GRI, SASB, TCFD, and UNGC frameworks to ensure transparency in its ESG performance.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2023
Type: SR
Pages: 55
Hikma Pharmaceuticals PLC
The report highlights Hikma's commitment to advancing health and wellbeing, empowering people, protecting the environment, and building trust. Key achievements in 2023 include a 15% reduction in Scope 1 and 2 emissions since 2020, donating $4.9 million worth of medicines, and achieving a 98% completion rate for ethics and compliance training. The company also focused on diversity, aiming for at least 35% women in leadership by 2025, and conducted energy audits across several MENA sites. Furthermore, Hikma aligned its reporting with GRI, SASB, TCFD, and UNGC frameworks to ensure transparency in its ESG performance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees